Strategy to reduce free radical species in Alzheimer’s disease: an update of selected antioxidants
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD), characterized by progressive loss of memory, language, reasoning and other cognitive functions, including dementia, is characterized pathologically by the presence of senile plaques, neurofibrillary tangles and synapse loss. Increased oxidative/nitrosative stress, decreased antioxidants, mitochondrial damage and other factors play major roles in the development and progression of AD. Strategies to reduce pro-oxidant species to ameliorate AD pathology have been proposed with mixed results. In this review, we focus on the most recent in vitro and in vivo antioxidant approaches for removing oxidant species with relevance to AD, including N-acetyl-l-cysteine, vitamin D, vitamin E, ferulic acid, tricyclodecan-9-yl-xanthogenate, selenium and melatonin as therapeutic stratagems in AD management. In addition, we reviewed the most effective mitochondria targeted antioxidants such as coenzyme Q10 and lipoic acid. We suggest the use of multitargeted approaches by formulas containing one or more antioxidant compounds may be more promising than single-agent approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Rayman, M. P. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61452-9 · Cited by 3,563
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Mitochondrial abnormalities in Alzheimer's disease
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03017.2001 · Cited by 1,367 · cited 1×
“A number of mitochondrial and metabolic abnormalities have been identified in neurons of AD compared with agematched controls that most likely lead to increased ROS production and reduction in energy stores, thus contributing to the neurodegenerative process [28–30].”
BackgroundTargeting Antioxidants to Mitochondria by Conjugation to Lipophilic Cations
Murphy, M. P., & Smith, R. A. J. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105110 · Cited by 1,173 · cited 1×
“MitoQ is a triphenylphosphonium-linked ubiquinone derivative that concentrates several 100-fold in mitochondria due to the large mitochondrial membrane potential and converts H2O2 to H2O and O2, reducing toxic insults from free radicals in the mitochondria [228,229].”
BackgroundLips, P. (2006) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2006.02.016 · Cited by 1,173 · cited 1×
“Vitamin D2 (ergocalciferol) is present in plants, yeast and fungi [176,177], while vitamin D3 (cholecalciferol) can be obtained from animal sources such as oily fish and egg yolk [176–178].”
BackgroundEvidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide
Butterfield, D. A., Drake, J., Pocernich, C., & Castegna, A. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02173-6 · Cited by 1,114
Self-citationDietary Intake of Antioxidants and Risk of Alzheimer Disease
Engelhart, M. J. (2002) · JAMA · doi:10.1001/jama.287.24.3223 · Cited by 1,080
Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease
Mecocci, P., MacGarvey, U., & Beal, M. F. (1994) · Annals of Neurology · doi:10.1002/ana.410360510 · Cited by 1,037 · cited 2×
“Involvement of oxidative stress in AD development & progression Abundant evidence supports the notion that oxidative/ nitrosative stress (OS) has a major role in the pathogenesis of AD leading to the damage of vital cellular components such as proteins, lipids and nucleic acids [7–12].”
Background
Cited by
Luteolin as an anti-inflammatory and neuroprotective agent: A brief review
Nabavi, S. F., Braidy, N., Gortzi, O., Sobarzo-Sanchez, E., Daglia, M., Skalicka-Woźniak, K., & Nabavi, S. M. (2015) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2015.09.002 · Cited by 480
Free radicals and polyphenols: The redox chemistry of neurodegenerative diseases
Losada-Barreiro, S., & Bravo-Díaz, C. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.061 · Cited by 289
Perluigi, M., Di Domenico, F., & Butterfield, D. A. (2024) · Physiological Reviews · doi:10.1152/physrev.00030.2022 · Cited by 282
Self-citationOxidant/Antioxidant Imbalance in Alzheimer’s Disease: Therapeutic and Diagnostic Prospects
Wojsiat, J., Zoltowska, K. M., Laskowska-Kaszub, K., & Wojda, U. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6435861 · Cited by 221
Di Domenico, F., Barone, E., Perluigi, M., & Butterfield, D. A. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6759 · Cited by 114
Self-citation
Metadata
- Authors
- Di Domenico, F., Barone, E., Perluigi, M., & Butterfield, D. A.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2014-09-22
- Volume
- 15
- Issue
- 1
- Pages
- 19-40
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2056092147
- Cited by
- 102
- References
- 55
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Strategy to reduce free radical species in Alzheimer’s disease: an update of selected antioxidants. https://app.cochat.ai/papers/10.1586/14737175.2015.955853
- The paper
- Di Domenico, F., Barone, E., Perluigi, M., & Butterfield, D. A. (2015). Strategy to reduce free radical species in Alzheimer’s disease: an update of selected antioxidants. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.2015.955853
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.